Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2006;2(3):285-302.
doi: 10.2147/vhrm.2006.2.3.285.

Metabolic syndrome: the danger signal in atherosclerosis

Patrick Mathieu  1 , Philippe Pibarot, Jean-Pierre Després
Affiliations
Review

Metabolic syndrome: the danger signal in atherosclerosis

Patrick Mathieu et al. Vasc Health Risk Manag. 2006.

Abstract

Atherosclerosis is a chronic inflammatory disease characterized by infiltration of blood vessels by lipids and leukocytes. There is a growing body of evidence that among risk factors that promote atherosclerosis, the metabolic syndrome is a powerful and prevalent predictor of cardiovascular events. The systemic inflammatory process associated with the metabolic syndrome has numerous deleterious effects that promote plaque activation, which is responsible for clinical events. Interactions between the innate immune system with lipid-derived products seem to play a major role in the pathophysiology of atherosclerosis in relation with the metabolic syndrome. The multiple links among adipose tissue, the vascular wall, and the immune system are the topics of this review, which examines the roles of oxidized low-density lipoprotein, inflammatory cytokines, and adipokines in triggering and perpetuating a danger signal response that promotes the development of atherosclerosis. Furthermore, therapeutic options that specifically target the metabolic syndrome components are reviewed in light of recent developments.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Peroxisome proliferators-activated receptor (PPAR-γ) is a member of nuclear receptor superfamily that regulates in macrophages numerous functions that have important impact on the development of atherosclerosis. It up-regulates the expression of the CD-36 scavenger receptor and has therefore a potential to increase atherosclerosis (in red). On the other hand, PPAR-γ reduces the expression of pro-inflammatory mediators and increases LXR expression, a nuclear receptor that control the level of adenosine triphosphate (ATP)-binding cassette protein-1 (ABCA-1), which mediates the apo-A1 mediated reverse cholesterol transport (green). Thus, the balance of PPAR-γ activity indicates that an antiatherosclerotic effect (green) might be superior to the pro-atherosclerotic effect (red), explaining the beneficial effect of the thiazolidinediones (TZDs). Abbreviations: apo-A1, apolipoprotein A1; CCR2, CC-chemokine receptor 2; IL-1β, interleukin 1β; IL-6, interleukin 6; LXRα, liver X nuclear receptor; ox-LDL, oxidized low-density lipoprotein; TNF-α, tumor necrosis factor-α.
Figure 2
Figure 2
The metabolic syndrome is characterized by visceral obesity and its attendant metabolic perturbations that have numerous pro-atherosclerotic effects on the arterial wall. Production of small dense LDL particles and decrease HDL levels increase vascular infiltration by lipids and the production of oxidized LDL (ox-LDL). Ox-LDL delivers a danger signal to the macrophages and the production of foam cells producing cytokines and growth factors that will promote the development of atherosclerosis. In addition, elevated blood levels of cytokines and of adipokines contribute to increase the inflammatory reaction. Abbreviations: apo A1, apolipoprotein A1; apo B, apolipoprotein B; AT1-R, angiotensin 1 receptor; CRP, C-reactive protein; HDL-C, high-density lipoproteincholesterol; HSPs, heat shock proteins; IL-1β, interleukin 1β; IL-6, interleukin 6; INF-γ, interferon-γ LDL-C, low-density lipoprotein-cholesterol; MCP-1, monocyte chemotactic protein 1; MMPs, matrix metalloproteinases; TNF-α, tumor necrosis factor-α.
Figure 3
Figure 3
Visceral obesity is a key component of the metabolic syndrome. Free fatty acids (FFA) and interleukin 6 (IL-6) produced by abdominal fat cells are drained up to the liver via the portal vein and contribute to the production of very low-density lipoprotein (VLDL) and C-reactive protein (CRP). VLDL through exchange of cholesteryl esters and triglycerides (TGs) contribute to the generation of highly atherogenic small and dense low-density lipoprotein (LDL) particles that are easily transformed to oxidized products that deliver a danger signal. In addition, abdominal fat cells produce resistin and leptins that deliver a danger signal, whereas lower levels of adiponectin contribute to amplify the pro-atherogenic signal through the loss of its protective effects. Abbreviations: ox, oxidized; Th-1, T helper 1.
See this image and copyright information in PMC

Comment in

  • Metabolic syndrome: sign of things to come.
    Tabrizchi R. Tabrizchi R. Vasc Health Risk Manag. 2006;2(3):193-4. doi: 10.2147/vhrm.2006.2.3.193. Vasc Health Risk Manag. 2006. PMID: 17326325 Free PMC article. No abstract available.

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. ACCORD trial. Accord trial [online] 2006. Accessed 22 January 2006. URL: http://www.accordtrial.org/
    1. Alberti KG, Zimmet PZ. Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus provisional report of a WHO consultation. Diabet Med. 1998;15:539–53. - PubMed
    1. [AHA] American Heart Association. Heart disease and stroke statistics – 2006 update [online] 2006. Accessed 12 June 2006. URL: http://www.americanheart.org/presenter.jhtml - PubMed
    1. Ansell BJ, Navab M, Hama S, et al. Inflammatory/antiinflammatory properties of high-density lipoprotein distinguish patients from control subjects better than high-density lipoprotein cholesterol levels and are favorably affected by simvastatin treatment. Circulation. 2003;108:2751–6. - PubMed
    1. Assmann G, Gotto AM., Jr HDL cholesterol and protective factors in atherosclerosis. Circulation. 2004;109:III8–14. - PubMed

Publication types

MeSH terms